Obesity Clinical Trial
Official title:
Pilot Study of Branched Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.
Despite the demonstrable health and quality of life benefits, there are unknowns within
consequences of obesity surgery. Weight loss composition is poorly understood. The objective
is to have a significant loss of body fat and a limited loss of muscular weight.
A cohort study in the nutrition unit at Toulouse University Hospital shows that 3 months and
1 year after surgery, there are 2 phenotypes of patients. The first one is called 'little
loss' and is defined by a contribution of muscular weight lower than 15% of the total weight
loss. The other one is called 'big loss' and is defined by a contribution of muscular weight
higher than 15% of the total weight loss. Causes of these different phenotypes are unknown
for the moment.
Some amino acids have an anabolic potential. Leucine induces a muscular protein synthesis in
clinical situations like hepatic cirrhosis, and some populations like new born and older
people.
Assuming that, a leucine-enriched essential amino acid supplementation will have a benefit
effect on the muscular mass. That is testing the influence of the quality of protein
consumed, more than the quantity. An anabolic substance (amino acid here) can lead to gain of
muscle only if it is associated to regular physical training, all patients will follow a
physical training.
An excessive loss of lean mass could have negative metabolic consequences. Indeed, lean mass
is an essential determinant of weight loss and of the glycaemia regulation. An important loss
of muscular mass could expose the person to a reduction of quality of life (because of
fatigue), or even a functional loss. Muscles are important for insulin sensibility and
glucose metabolism. Muscles are proteolysis target and proteins will be used as sources of
amino acid for other cellular functions.
Changes in lean mass have been at the centre of several studies, but changes in muscular mass
after bariatric surgery have been report only one time.
A cohort study in the nutrition unit at Toulouse University Hospital shows that 3 months and
1 year after surgery, there are 2 phenotypes of patients. The first one is called 'little
loss' and is defined by a contribution of muscular weight lower than 15% of the total weight
loss. The other one is called 'big loss' and is defined by a contribution of muscular weight
higher than 15% of the total weight loss. Causes of these different phenotypes are unknown
for the moment. Nothing distinguishes them before the surgery. Type of surgery, gender,
protein intake (in grams of proteins intake per day) do not appear to have a determining
influence about the intensity of muscle mass loss. The only other study published shows
changes in muscular mass about 15% at 6 weeks.
Relation between glycaemia changes and muscle mass changes suggests that patients with modest
changes in muscular mass are patients who have the best improvement of glycaemia after
surgery. It is the reason why, it could be interesting to preserve muscular mass.
Nowadays, there is no consensual strategy to compensate this loss of muscle mass. It is
important to have in the same time an anabolic stimulus (training, hormoneā¦) and a sufficient
energy and protein intake.
According to a recent study which compares leucine intake with placebo during weight loss
driven by a low-calorie diet associated to a muscle strengthening exercises, patients loss
the same weight, but leucin group is gaining lean mass, while placebo group is losing it.
Accordingly, twe different doses of amino acid will be tested of those used as diet
supplement.
This study is testing the influence of the quality of protein consumed, more than the
quantity. Patients will take leucine-enriched amino acid supplement and follow physical
training. Aromatic amino acid supplementation showed an anabolic effect in older people,
undernourished children and undernourished patients with chronic obstructive pulmonary
disease. There are no known side effects. This amino acid supplementation has not been
evaluated in post-obesity surgery context.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |